Merck & Company Inc (MRK)vsBeyond Air Inc (XAIR)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
XAIR
Beyond Air Inc
$0.41
-8.09%
HEALTHCARE · Cap: $4.71M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 949756% more annual revenue ($65.77B vs $6.92M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
XAIR
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for XAIR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 104.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -240.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : XAIR
The strongest argument for XAIR centers on Price/Book, Revenue Growth. Revenue growth of 104.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : XAIR
The primary concerns for XAIR are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 3.06 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while XAIR is a hypergrowth play — different risk/reward profiles.
XAIR carries more volatility with a beta of 0.23 — expect wider price swings.
XAIR is growing revenue faster at 104.7% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 43/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Beyond Air Inc
HEALTHCARE · MEDICAL DEVICES · USA
Beyond Air, Inc., a clinical-stage biopharmaceutical and medical device company, develops nitric oxide (NO) generators and delivery systems. The company is headquartered in Garden City, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?